期刊
NATURE REVIEWS CANCER
卷 17, 期 7, 页码 425-440出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc.2017.40
关键词
-
类别
资金
- V Foundation for Cancer Research
- National Institutes of Health/National Cancer Institute [R01CA178397, R21CA205936]
- Leukemia and Lymphoma Society [GCNCR0314UTAH]
- Leukemia and Lymphoma Society
- Gabrielle's Angel Foundation for Cancer Research
- National Cancer Institute [5R00CA151457-04, 1R01CA183947-01]
- Ligue Nationale Contre le Cancer (Equipe labellisee)
- INCa [PRT2013 H78016, INCA_8073]
- Investissements d'Avenir (Molecular Medicine in Oncology program)
Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) are aggressive myeloid malignancies recognized as a distinct category owing to their unique combination of dysplastic and proliferative features. Although current classification schemes still emphasize morphology and exclusionary criteria, disease-defining somatic mutations and/or germline predisposition alleles are increasingly incorporated into diagnostic algorithms. The developing picture suggests that phenotypes are driven mostly by epigenetic mechanisms that reflect a complex interplay between genotype, physiological processes such as ageing and interactions between malignant haematopoietic cells and the stromal microenvironment of the bone marrow. Despite the rapid accumulation of genetic knowledge, therapies have remained nonspecific and largely inefficient. In this Review, we discuss the pathogenesis of MDS/MPN, focusing on the relationship between genotype and phenotype and the molecular underpinnings of epigenetic dysregulation. Starting with the limitations of current therapies, we also explore how the available mechanistic data may be harnessed to inform strategies to develop rational and more effective treatments, and which gaps in our knowledge need to be filled to translate biological understanding into clinical progress.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据